Cramer likes Sanofi because three of its biggest drugs are going generic this year, but the company saw the dangers coming and took steps to make sure it never happens again. He hands it to the company’s management, who he praised for their strategic thinking and leadership.

Going forward, the company is investing in high growth platforms that are protected by more than just a patent, such as vaccines where barriers to entry are high, diabetes and generics. In doing so, the company hopes to build brand loyalty.Cramer thinks Sanofi is a buy, buy, buy.

Bristol-Myers and Pfizer

Bristol-Myers and Pfizer have been working on a groundbreaking drug called Eliquis, an oral anticoagulant that prevents stroke in patients with atrial fibrillation, which is the most common form of cardiac arrhythmia or irregular heartbeat. It appears to be highly effective and could be a needle mover, too. If approved in March, the drug could generate more than $5 billion in peak sales with the money being divided between the two companies.

Cramer said Eliquis is just one reason to own Bristol-Myers and Pfizer, though. Both stocks sports juicy dividend yields of 4.3 and 4 percent respectively.

Johnson & Johnson.

SNY News & Analysis

 Amyris slips after firm starts securities lawsuit - 16 May 2013 EDT

 FDA approves labels with lower doses for zolpidem sleep drugs - 14 May 2013 EDT

 A taste for defensives sours prospects for European stocks - 14 May 2013 EDT

 Drug Spending Drops for the First Time in 55 Years - 09 May 2013 EDT

 European shares slip from multi-year highs - 09 May 2013 EDT

 More SNY News